Administration of a tropomyosin receptor kinase inhibitor attenuates sarcoma-induced nerve sprouting, neuroma formation and bone cancer pain

Pain often accompanies cancer and most current therapies for treating cancer pain have significant unwanted side effects. Targeting nerve growth factor (NGF) or its cognate receptor tropomyosin receptor kinase A (TrkA) has become an attractive target for attenuating chronic pain. In the present repo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghilardi, Joseph R, Freeman, Katie T, Jimenez-Andrade, Juan M, Mantyh, William G, Bloom, Aaron P, Kuskowski, Michael A, Mantyh, Patrick W
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004846/
https://www.ncbi.nlm.nih.gov/pubmed/21138586
http://dx.doi.org/10.1186/1744-8069-6-87

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004846/
https://www.ncbi.nlm.nih.gov/pubmed/21138586
http://dx.doi.org/10.1186/1744-8069-6-87

Ejemplares similares